Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments

Ethel D. Weld, Jacqueline Astemborski, Gregory D. Kirk, Mark S. Sulkowski, Stephanie Katz, Richard Rothman, Sunil S. Solomon, Gail V. Matthews, Yu Hsiang Hsieh, Malvika Verma, Giovanni Traverso, Susan Swindells, Andrew Owen, Jordan Feld, Charles Flexner, Shruti H. Mehta, David L. Thomas

Research output: Contribution to journalArticlepeer-review


Background: Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-Acting HCV treatment. Methods: A cross-sectional, 43-question survey was administered to 1457 individuals with or at risk of HCV at 28 sites in 9 countries to assess comparative interest in a variety of long-Acting strategies in comparison with oral pills. Results: Among HCV-positive participants, 37.7% most preferred an injection, 5.6% an implant, and 6% a gastric residence device, as compared with 50.8% who stated they would most prefer taking 1-3 pills per day. When compared directly to taking pills, differences were observed in the relative preference for an injection based on age (P<.001), location (P<.001), and prior receipt of HCV treatment (P=.005) but not sex. When an implant was compared with pills, greater preference was represented by women (P=.01) and adults of younger ages (P=.01 per 5 years). Among participants without HCV, 49.5% believed that injections are stronger than pills and 34.7% preferred taking injections to pills. Among those at-risk participants who had received injectable medications in the past, 123 of 137 (89.8%) expressed willingness to receive one in the future. Conclusions: These data point to high acceptability of long-Acting treatments, which for a substantial minority might even be preferred to pills for the treatment of HCV infection. Long-Acting treatments for HCV infection might contribute to global efforts to eliminate hepatitis C.

Original languageEnglish (US)
Pages (from-to)3-10
Number of pages8
JournalClinical Infectious Diseases
Issue number1
StatePublished - Jul 1 2022


  • Acting Treatments Patient Preferences Medication Acceptability Novel Drug Delivery Methods
  • Hepatitis C Long

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments'. Together they form a unique fingerprint.

Cite this